Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kaken Files Vascular Malformation Drug in Japan, Eyes FY2027 Approval
Kaken Pharmaceutical said on May 15 that it has filed for regulatory approval in Japan for KP-001 (serabelisib), its investigational treatment for refractory vascular malformations. The application is based on data from a domestic PIII trial, with the company aiming…
To read the full story
Related Article
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
BUSINESS
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Nxera to Earn US$10 Million Milestone as Alzheimer’s Candidate Moves to PII
August 27, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…